Denosumab — NZ Medication Guide
📋 Reviewed by a Registered Pharmacist NZ — This information is for general educational purposes only and does not replace professional medical advice. Always consult your doctor or pharmacist before starting, stopping, or changing any medication.
What is Denosumab?
Denosumab (brand name Prolia®) is a monoclonal antibody that inhibits bone resorption, used for the treatment of osteoporosis and cancer-related bone loss. This medication is commonly prescribed in New Zealand and is funded by Pharmac with Special Authority criteria for osteoporosis.
What is Denosumab Used For?
Denosumab (Prolia®) is used for postmenopausal osteoporosis at high fracture risk, male osteoporosis, and glucocorticoid-induced osteoporosis. In higher doses (Xgeva®), it is used to prevent skeletal complications from bone metastases.
How Does Denosumab Work?
Denosumab is a fully human monoclonal antibody that binds to RANK ligand (RANKL), a key mediator of osteoclast formation and activity. By blocking RANKL, it markedly reduces osteoclast-mediated bone resorption, increasing bone mineral density and reducing fracture risk.
How to Take Denosumab
Administered as a subcutaneous injection (60 mg Prolia®) every 6 months, given by a healthcare professional. Ensure adequate calcium and vitamin D supplementation throughout treatment. Do not discontinue denosumab without discussing with your doctor, as stopping can cause a rapid and significant rebound in bone loss.
Common Side Effects of Denosumab
- Back pain
- Musculoskeletal pain
- High blood pressure
- Urinary tract infections
- Upper respiratory infections
- Skin reactions at injection site
Serious Side Effects — Seek Medical Attention
Contact your doctor or call 111 immediately if you experience any of the following:
- Hypocalcaemia (low blood calcium — particularly in patients with vitamin D deficiency or kidney disease)
- Osteonecrosis of the jaw (ONJ — rare but serious)
- Atypical femoral fractures (rare)
- Rebound vertebral fractures on discontinuation
- Serious infections (cellulitis, urinary tract infections)
Drug Interactions
Denosumab may interact with other medicines. Always inform your doctor and pharmacist of all medications, supplements, and herbal products you are taking. Key interactions include:
- Other bone-modifying agents (should not be combined with bisphosphonates routinely)
- Immunosuppressants (additive infection risk)
New Zealand Prescribing Information
Prolia® (denosumab 60 mg) is funded by Pharmac under Special Authority for patients with postmenopausal osteoporosis who have experienced a fragility fracture or have very low bone density, and who have failed or are intolerant of bisphosphonate therapy. It is administered by a nurse or GP every 6 months. Calcium and vitamin D supplementation is mandatory during treatment.
Frequently Asked Questions
What happens if I miss a denosumab injection?
Contact your doctor as soon as possible. Missing a dose of Prolia® can lead to rapid bone loss — studies show that discontinuing denosumab can cause rebound bone loss that significantly increases fracture risk. Never stop without medical supervision.
Can I take calcium supplements with denosumab?
Yes — calcium and vitamin D supplementation are mandatory during denosumab treatment, particularly in the first few weeks after an injection when hypocalcaemia risk is highest. Your doctor will usually prescribe these alongside your injection.
⚠️ Disclaimer: This page is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or a qualified health provider with any questions you may have regarding a medical condition or medication. In New Zealand, medication availability and funding may vary — check with Pharmac or your pharmacist for the most current information.
Reviewed by a Registered Pharmacist NZ
References & Further Information
The following New Zealand and international resources were used to inform this page: